×

BRIEF-Ablynx says ALX-0061 study positive

BRUSSELS, Oct 4 (Reuters) - Ablynx NV :

* Ablynx reports excellent interim results from phase i/ii study with its

anti-il-6r nanobody, ALX-0061, in rheumatoid arthritis patients

* Says ALX-0061 was well-tolerated

((Brussels newsroom; +32 2 287 6810))

((For more news, please click here ))